SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc. (RPRX)

NEW YORK, July 17, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repros Therapeutics Inc. ("Repros" or the "Company") (NASDAQ: RPRX). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/rprx.

The investigation concerns whether Repros and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On July 17, 2017, Repros revealed that it received preliminary feedback from the U.S. Food and Drug Administration ("FDA") regarding its clinical development program for Proellex, its oral delivery mechanism for telapristone acetate.  Repros said that "[t]he Proellex program will remain on partial clinical hold, and based upon the FDA's review of all the existing liver function safety data, the FDA has indicated that the Company will be required to compile a large pre-approval safety data base to support future development."  Repros also said that "a much larger clinical trial, with associated time and cost requirements, would be necessary."  Following this news, Repros stock dropped over 30% during intraday trading on July 17, 2017.

If you are aware of any facts relating to this investigation, or purchased shares of Repros, you can assist this investigation by visiting the firm's site: www.bgandg.com/rprx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

View original content with multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-repros-therapeutics-inc-rprx-300489135.html

SOURCE Bronstein, Gewirtz & Grossman, LLC